Cell & Gene therapies: Addressing Manufacturing Challenges to Accelerate Innovation

Cell & Gene Therapies bring a promising future for many serious and rare disease patients. However, manufacturing these treatments represent a lot of challenges and can represent a barrier to the development and thus limiting broader access to these promising cures.
Seqens, with the ongoing acquisition of CELLforCURE, has the ambition to rapidly develop strategic capabilities, unique to Europe, that would:
Encourage closer collaboration between the hospitals, companies and manufacturers in the interest of the patients, Foster a breath of potentially innovative modalities tailored to the changing market, Have the potential to bring new therapies to patients faster.